Skip to main content

CORRECTION article

Front. Oncol., 12 March 2018
Sec. Cancer Immunity and Immunotherapy
Volume 8 - 2018 | https://doi.org/10.3389/fonc.2018.00047

Corrigendum: Metastatic Extramammary Paget’s Disease: Pathogenesis and Novel Therapeutic Approach

This article is a correction to:

  1. Metastatic Extramammary Paget’s Disease: Pathogenesis and Novel Therapeutic Approach

    1. Read original article
\r\nKeitaro Fukuda,Keitaro Fukuda1,2Takeru Funakoshi*\r\nTakeru Funakoshi2*
  • 1Department of Dermatology, University of Massachusetts Medical School, Worcester, MA, United States
  • 2Department of Dermatology, Keio University School of Medicine, Tokyo, Japan

A corrigendum on

Metastatic Extramammary Paget’s Disease: Pathogenesis and Novel Therapeutic Approach
by Fukuda K, Funakoshi T. Front Oncol (2018) 8:38. doi: 10.3389/fonc.2018.00038

In the published article, there was an error in the number of ongoing clinical trial for HER2-positive unresectable or metastatic EMPD “(UMIN-000006629)”. Instead of “(UMIN-000006629)”, it should be “(UMIN000021311)”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article has been updated.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: metastatic extramammary Paget’s disease, HER2–PI3K/ERK signaling, lymphangiogenesis, CXCR4–stromal cell-derived factor-1 axis, CD163+M2 macrophage, receptor activator of nuclear factor kappa-B ligand–RANK signaling, mismatch-repair deficient, anti-PD-1 antibody

Citation: Fukuda K and Funakoshi T (2018) Corrigendum: Metastatic Extramammary Paget’s Disease: Pathogenesis and Novel Therapeutic Approach. Front. Oncol. 8:47. doi: 10.3389/fonc.2018.00047

Received: 19 February 2018; Accepted: 19 February 2018;
Published: 12 March 2018

Copyright: © 2018 Fukuda and Funakoshi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Approved by: Frontiers in Oncology Editorial Office, Frontiers, Switzerland

*Correspondence: Takeru Funakoshi, takeruf@a8.keio.jp

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.